Mode of Action

Revestive mimics naturally occurring GLP-2 and results in physiologically enhanced absorption in patients with short bowel syndrome-intestinal failure1-3

Naturally occurring GLP-2, an intestinal hormone, plays an important role in maintaining the normal structure and function of the small intestine and in the absorption of nutrients4-6

GLP-2 secretion1,4-6

Maintains mucosal integrity and increases growth (villus height and crypt depth)

Reduces motility, gastric acid secretion, and intestinal inflammation intensity

Increases intestinal and portal blood flow

Facilitates the absorption of nutrients

Secretion of naturally occurring GLP-2 is significantly impaired in patients with short bowel syndrome-intestinal failure (SBS-IF) compared to non-SBS patients7

Revestive is a recombinant analogue of human GLP-2 with a longer half-life than naturally occurring GLP-21

In patients with SBS-IF, Revestive:1,3

  • Physiologically enhanced absorption
  • Increased intestinal villus height and crypt depth vs baseline*
  • Stimulated intestinal rehabilitation and increased the absorptive capacity of the intestine**

Revestive increased intestinal villus height and crypt depth vs. baseline3

*In a 21-day, Phase II, open-label, multicentre, dose-ranging study evaluating the safety and effect of Revestive in 17 patients with SBS-IF, treatment with Revestive at doses from 0.03 to 0.15 mg/kg/day in single or divided doses. 8 of 10 patients with end jejunostomy were biopsied and found to have increased intestinal villus height and crypt depth, compared with baseline.

** Treatment resulted in enhanced gastrointestinal fluid absorption of approximately 750-1000 mL/day with improvements in the absorption of electrolytes.

GLP-2= glucagon-like peptide-2; SBS-IF= short bowel syndrome – intestinal failure


  1. Revestive (teduglutide) Summary of Product Characteristics. Shire Pharmaceuticals Ireland Limited, Dublin, Ireland. November 2017.
  2. Hofstetter S, Stern L, Willet J. Key issues in addressing the clinical and humanistic burden of short bowel syndrome in the US. Curr Med Res Opin. 2013;29:495-504.
  3. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54:1224-1231.
  4. Wallis K, Walters JR, Gabe S. Short bowel syndrome: the role of GLP-2 on improving outcome. Curr Opin Clin Nutr Metab Care. 2009;12:526-532.
  5. Tee CT, Wallis K, Gabe SM. Emerging treatment options for short bowel syndrome: potential role of teduglutide. Clin Exp Gastroenterol. 2011;4:189-196.
  6. Drucker DJ, Yusta B. Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.
  7. Jeppesen PB, Hartmann B, Hansen BS, Thulesen J, Holst JJ, Mortensen PB. Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure Gut. 1999;45:559-563.

The information on this website is intended for an international healthcare professional audience outside of the United States, United Kingdom, and Ireland only.